Heather Kaufman, DPM
Foot Surgery · Anchorage, AKNPI 1710007091
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Smith+Nephew at 34.0% of the total. Reporting peaked in 2022 at $3,315 and has fallen 95.3% since, to $156 in 2025.
Across 110 payments — averaging $75.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$3K
- Summit Surgical Corp.$2K
- Paragon 28, Inc.$1K
- Organogenesis Inc.$306
- Stryker$305
- Amgen$251
- plus $1K from 17 others
What the payments were for
- Travel & lodging$2,58531%
- Food & beverage$3,29440%
- Education$2,40029%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 47 | $2,819 |
| Summit Surgical Corp. | 2 | $2,400 |
| Paragon 28, Inc. | 6 | $1,086 |
| Organogenesis Inc. | 15 | $306 |
| Stryker | 7 | $305 |
| Amgen | 10 | $251 |
| Kerecis Limited | 2 | $180 |
| RSW Medical Company, Inc. | 1 | $119 |
| Johnson & Johnson | 1 | $113 |
| Vaporox, Inc. | 1 | $100 |
| Tactile Systems Technology Inc | 3 | $95 |
| Zimmer Biomet | 1 | $88 |
| Triad Life Sciences Inc. | 1 | $80 |
| Heron Therapeutics, Inc. | 2 | $80 |
| Solventum Corporation | 1 | $67 |
| ANI Pharmaceuticals, Inc. | 2 | $48 |
| Abbott | 2 | $27 |
| Baudax Bio Inc. | 1 | $22 |
| Tenex Health Inc. | 1 | $21 |
| Medtronic | 1 | $20 |
| Celularity Inc. | 1 | $18 |
| Nevro Corp. | 1 | $18 |
| Bioventus LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERSAJET II$1,103
- Renasys$1,103
- Grafix$1,103
- PICO$1,103
- Oasis$1,103
- Stravix$843
- Lapidus$754
- Kerecis Omega3 SurgiClose$518
- Kerecis Omega3 GraftGuide$173
- Kerecis Omega3 Marigen$173
- Product Portfolio$137
- N/A$113
- MOTOBAND$113
- FIBERGRAFT Aeridyan Matrix$113
How this compares
Too few foot surgery providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 50 | $530 |
| Cephalexin | 14 | $220 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.